Peptide Statistics 2026: 60+ Key Facts

The GLP-1 receptor agonist class generated $62.83 billion in 2025 (Fortune Business Insights). That single drug class now produces more revenue than the entire peptide therapeutics market did five years ago. Its projected CAGR of 16.8% through 2032 outpaces every other peptide segment.

Semaglutide (branded as Ozempic and Wegovy) produced roughly $26 billion in combined revenue for Novo Nordisk in fiscal year 2024. Tirzepatide (Mounjaro and Zepbound) generated $16.47 billion for Eli Lilly over the same period.

By Q3 2025, tirzepatide became the world's best-selling drug, surpassing Merck's Keytruda. Eli Lilly reported $10.1 billion in tirzepatide revenue for that single quarter and raised its full-year 2025 guidance to $63 billion. Two companies now control virtually all GLP-1 revenue. No other pharmaceutical segment shows this level of duopoly concentration.

JPMorgan analysts project 25 to 30 million Americans will take GLP-1 drugs by 2030, up from roughly 15 million today. Research and Markets forecasts the GLP-1 market alone will reach $137.4 billion by that year.

The broader peptide therapeutics market is projected to hit $87.2 billion by 2035 (GlobeNewsWire, December 2025). Cancer, diabetes, and metabolic disorders remain the primary growth drivers. For dosage planning on the most prescribed peptide drug, see our semaglutide dosage calculator.

Sources: Novo Nordisk FY2024 earnings; Eli Lilly FY2024 earnings; BioSpace; BioPharma Dive.

Ozempic alone outsells most pharmaceutical companies' entire portfolios. Its $18 billion in annual revenue exceeds the total revenue of Regeneron, Biogen, or Moderna. The weight-management indication (Wegovy, Zepbound) is the faster-growing segment, but the diabetes indication still generates the larger share of revenue.

A KFF tracking poll from late 2025 found that 1 in 8 U.S. adults (12.4%) reported currently taking a GLP-1 drug for weight loss, diabetes, or another condition. That figure doubled from 5.8% just 18 months earlier.

Medicaid GLP-1 prescriptions surged from 1.3 million in 2019 to 8.4 million in 2024 (KFF Medicaid spending data). The growth is concentrated in the obesity indication, not diabetes. That shift reflects the cultural transformation of GLP-1 drugs from diabetes treatment to weight management tool.

The FDA approved oral semaglutide (Wegovy) for weight management in December 2025. It was the first GLP-1 pill approved for obesity. Novo Nordisk set the list price at $149 per month without insurance, undercutting the injectable version by more than 70%.

Clinical trials showed 16.6% body weight loss at 64 weeks with the oral formulation. Patients who avoided injections now have a daily pill option. Analysts expect oral GLP-1s to expand the total addressable market by 30 to 40%.

The injection barrier kept millions of potential patients on the sideline. A daily pill eliminates that barrier. For injection guidance on current formulations, see our tirzepatide dosage calculator.

Source: DataForSEO (U.S. Google Ads data). Analysis by PeptidesExplorer.

Three patterns stand out in this data.

Safety and legality queries are growing fastest. "Are peptides safe" and "are peptides steroids" both exceeded 650% growth. This signals a wave of first-time consumers entering the market. People searching "are peptides steroids" have heard the word but do not yet understand what peptides are. That is new-market behavior.

Purchase-intent searches show explosive commercial demand. "How to get peptides" grew 1,019% in twelve months. "Where to buy peptides" grew 537%. These searchers have moved past curiosity into active purchasing decisions.

The comparison query "peptides vs steroids" grew 400%. Fitness communities are evaluating peptides as alternatives to anabolic compounds. The question itself implies familiarity with both categories and a desire to choose between them.

Approximately 100 peptide-based drugs have received regulatory approval worldwide as of 2025. Between 2016 and 2024, the FDA approved 34 new peptide therapeutics (MDPI Pharmaceuticals, 2025 review).

Over 200 peptide-related clinical trials were active on ClinicalTrials.gov during 2024 and 2025, spanning oncology, metabolic disease, neurology, and infectious disease. Peptide vaccines represented one of the fastest-growing trial categories.

The total number of peptide molecules in active clinical development exceeds 170 globally (Precedence Research, 2025). For context on how this expanding pipeline affects individual peptide users, see our getting started guide.

In late 2023, the FDA placed 19 widely used peptides on its Category 2 ("difficult to compound") list, restricting access through 503A and 503B compounding pharmacies. BPC-157, AOD-9604, and several others lost their compounding pathway.

On February 27, 2026, following advocacy from clinicians and patients, 14 of those 19 peptides were reclassified back to Category 1 (eligible for compounding). The reclassification was announced but had not yet been formally published in the Federal Register as of March 2026.

The practical impact: peptides that were only available through grey-market vendors can now be legally prescribed by a physician and prepared by a licensed pharmacy. For the full regulatory timeline, see our analysis of the Peptide Sciences shutdown.

The Centers for Medicare & Medicaid Services (CMS) announced the BALANCE model in early 2026, launching July 2026. Medicare Part D beneficiaries with BMI above 30 (or 27 with comorbidities) will access GLP-1 drugs at a $50 per month copay.

Medicare previously excluded weight-loss drugs from coverage entirely. The BALANCE model is projected to cover 3.4 million beneficiaries in its first year. That single policy change could add billions in GLP-1 revenue while expanding access to the population segment most likely to benefit.

Gallup tracking data showed the U.S. adult obesity rate dropping from 39.9% in early 2024 to 37.0% by late 2025. That 2.9 percentage point decline translates to roughly 7.6 million fewer obese adults.

The CDC's National Center for Health Statistics confirmed the trend in Data Brief #537, noting a statistically significant decline in adult obesity prevalence beginning in late 2024. This is the first sustained decline in the U.S. obesity rate in over a decade. Researchers cautioned that the trend coincides with both GLP-1 adoption and updated measurement methodologies.

JPMorgan's 2026 healthcare research report found that GLP-1 users consume 21% fewer daily calories and spend 31% less on groceries compared to pre-treatment levels. The bank estimated that sustained adoption could reduce U.S. food and beverage industry revenue by $30 to $55 billion annually by 2030 to 2034.

Morgan Stanley published a parallel finding: bariatric surgery volumes have declined 15% in markets with high GLP-1 adoption. The surgical weight-loss industry is watching its patient pipeline shrink in real time.

A Pew Research Center analysis from January 2026 found that 53% of Americans view GLP-1 drugs favorably, up from 42% in 2024. Support is highest among adults who personally know someone taking the drugs. Public perception has shifted from skepticism ("celebrity diet drug") toward acceptance ("legitimate medical treatment").

Retatrutide is a triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. In Phase 3 trials, participants lost an average of 28.7% of their body weight (71.2 lbs) at 68 weeks. That result exceeds anything achieved by semaglutide or tirzepatide in comparable studies.

Eli Lilly has seven additional Phase 3 readouts expected throughout 2026, covering NASH (metabolic liver disease), sleep apnea, and cardiovascular outcomes. If approved, retatrutide would be the most effective weight-loss drug ever brought to market. For current efficacy and safety data, see our retatrutide side effects analysis.

Orforglipron is a small-molecule oral GLP-1 receptor agonist in Phase 3 development. Unlike oral semaglutide (still a peptide requiring fasting), orforglipron is a non-peptide compound that can be taken without food restrictions. Phase 2 data showed 14.7% body weight loss at 36 weeks.

If approved, orforglipron would simplify daily GLP-1 use and reach patients who refuse both injections and fasting-dependent pills. The convenience advantage could pull tens of millions of additional patients into the GLP-1 market.

Peptide research extends well beyond GLP-1 and obesity. Peptide-drug conjugates (molecules that deliver chemotherapy directly to tumor cells) represent one of the fastest-growing segments in cancer therapeutics, with over 30 candidates in active clinical trials as of 2025.

Antimicrobial peptides are advancing through development as antibiotic resistance worsens. Neurodegenerative disease programs are testing peptide approaches for Alzheimer's and Parkinson's. The total number of peptide molecules in active clinical development exceeds 170 globally (Precedence Research, 2025).

JPMorgan estimated that GLP-1 drugs could reduce caloric consumption across the U.S. population by 1.5 to 2.5% by 2030. For the food and beverage industry, that translates to $30 to $55 billion in lost annual revenue. Snack companies, fast food chains, and alcohol producers face the greatest exposure.

The impact is already visible. Restaurant chains reported lower average check sizes in markets with high GLP-1 adoption during Q3 2025 earnings calls. Consumer packaged goods companies are reformulating product lines toward smaller portions and higher protein content. A drug designed for diabetes is quietly reshaping the American food economy.

Peptide therapy fueled a parallel boom in telehealth clinics and compounding pharmacies. Search volume for "peptide therapy near me" holds steady at 12,100 monthly searches. "Peptide clinic" grew from 590 to 1,600 searches per month over 12 months (+171%).

503B outsourcing facilities that compound peptides saw revenue growth of 25 to 40% between 2024 and 2025 (industry trade publications). The FDA's evolving stance on compounding eligibility creates both opportunity and regulatory risk for this segment. For background on regulatory shifts, see our FDA peptide crackdown analysis.

Source: DataForSEO, February 2026. Approximate U.S. monthly averages.

The search hierarchy is steep. Semaglutide generates 20 times the search volume of BPC-157, the most-searched research peptide. Pharmaceutical GLP-1 drugs dominate public attention. Research peptides like TB-500 and GHK-Cu maintain dedicated audiences within fitness, biohacking, and longevity communities, but the scale difference is dramatic.

A 2023 study published in JAMA found that 42% of peptide products purchased online from non-pharmaceutical sources contained inaccurate quantities of the listed compound. Some contained no active peptide at all. Others contained unlisted contaminants.

This data point drives much of the regulatory scrutiny around grey-market peptide sales. The Peptide Sciences shutdown in March 2026 underscored the instability of unregulated supply chains. Independent testing by Finnrick showed quality scores ranging from A to E across the same vendor's product line.

For guidance on evaluating peptide sources, see our peptide safety guide and 2026 buyer's guide.